From transitioning a pediatric rheumatology patient to adult care to re-evaluating a missed diagnosis, in this slideshow, we highlight some key presentations from the annual Rheumatology Nurses Society meeting held last month.
Better communication between pediatric and adult rheumatologists is especially important as pediatric patients with juvenile idiopathic arthritis transition to adult care. In this Q&A, we revisit a Rheumatology Nurses Society annual meeting presentation made last month by Cathy Patty-Resk, MSN, RN, CPNP, a pediatric rheumatology nurse practitioner with the Children’s Hospital of Michigan.
Children with active rheumatic disease exposed to multiple biological drugs should be monitored for hypersensitivity reactions, particularly during intravenous infusions, say researchers writing in Pediatric Allergy and Immunology this month
Etanercept is a safe, well-tolerated medication for treating pediatric patients with extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, and psoriatic arthritis, according to the results for a new study.
In April, the FDA approved the etanercept biosimilar etanercept-ykro (Eticovo, Samsung Bioepis) for the same indications as its reference product Enbrel.
The American College of Rheumatology and the Arthritis Foundation have updated the 2013 treatment guidelines for juvenile idiopathic arthritis (JIA), which includes juvenile non-systemic polyarthritis, sacroiliitis, and enthesitis. In this slideshow, we highlight the recommendations.
Early treatment with DMARDs for juvenile idiopathic arthritis polyarthritis is now preferred over beginning patients on NSAID monotherapy, per updated treatment guidelines.
Real-world applications of non-biologic treatments in children with juvenile idiopathic arthritis may be effective in controlling or maintaining the condition in some patients, new research shows.
Children affected by juvenile idiopathic arthritis, manifesting as non-systemic polyarthritis, sacroilitis or enthesitis, have a number of therapeutic options available. In this article, we outline the options.
Historically, treatments for children with systemic juvenile idiopathic arthritis (sJIA) have been difficult and ineffective, leading to poor outcomes. But, findings from a new study point to a method that could lead to more positive results.